Bone Biologics (OTC:BBLG) Trading Down 1.3%

Bone Biologics Co. (OTC:BBLG) dropped 1.3% on Monday . The stock traded as low as $2.12 and last traded at $2.22. Approximately 14,995 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 124,527 shares. The stock had previously closed at $2.25.

Bone Biologics Trading Down 1.4 %

The firm has a market capitalization of $1.11 million, a price-to-earnings ratio of -0.04 and a beta of 0.18. The firm has a 50 day moving average price of $2.98 and a two-hundred day moving average price of $1.96.

Hedge Funds Weigh In On Bone Biologics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sabby Management LLC lifted its position in Bone Biologics by 21.2% during the 1st quarter. Sabby Management LLC now owns 1,500,000 shares of the company’s stock worth $388,000 after acquiring an additional 262,795 shares in the last quarter. Vanguard Group Inc. acquired a new position in Bone Biologics during the 1st quarter worth approximately $93,000. Finally, Jane Street Group LLC acquired a new position in Bone Biologics during the 1st quarter worth approximately $37,000.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1.